OncoSec Medical Inc (ONCSQ)

[dangerM]

Thanks for helping my understanding!

Well, I saw it as a technical breakthrough. Leaving out the viral vector (as they did) would rule out the problem of immunogenicity*. But of course, their other major disadvantage remains (using a only much smaller, less patient-specific antigen pool, or even only a single one). So of course, I still see Oncosec as uniquely and much better positioned! :o)

dM


* By the way, this is also why I am sceptical of oncolytic virus-approaches. They might lose efficiency when recognized by the immune system in case of re-treatment and might become less efficient then, when used at a second or third time. Oncosec of course does not have a limit on re-treatment (which is one of the very important highlights, as so many trials show that IO treatments need to work over time).